0 256

Cited 0 times in

Retrograde transvenous obliteration for the prevention of variceal rebleeding in patients with portal vein thrombosis: a multicenter study

Authors
 Jiaywei Tsauo  ;  Seung Yeon Noh  ;  Ji Hoon Shin  ;  Dong Il Gwon  ;  Kichang Han  ;  Jae Myeong Lee  ;  Ung Bae Jeon  ;  Young Hwan Kim 
Citation
 EUROPEAN RADIOLOGY, Vol.31(1) : 559-566, 2021-01 
Journal Title
EUROPEAN RADIOLOGY
ISSN
 0938-7994 
Issue Date
2021-01
MeSH
Aged ; End Stage Liver Disease* ; Esophageal and Gastric Varices* / complications ; Esophageal and Gastric Varices* / therapy ; Gastrointestinal Hemorrhage / prevention & control ; Humans ; Middle Aged ; Portal Vein ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome
Keywords
Embolization, therapeutic ; Esophageal and gastric varices ; Hypertension, portal ; Liver diseases
Abstract
Objectives: To evaluate the effectiveness of retrograde transvenous obliteration (RTO) for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis (PVT).

Methods: Consecutive cirrhotic patients with PVT who underwent RTO for the prevention of variceal rebleeding between January 2002 and June 2019 were included in this multicenter retrospective study. The primary outcome measure was rebleeding. The secondary outcome measures were survival, other complications of portal hypertension, liver function, and PVT.

Results: Forty-five patients (mean age, 66.0 ± 10.6 years; mean Model for End-Stage Liver Disease (MELD) score, 13.9 ± 5.5) were included. The 1-year actuarial probability of remaining free of rebleeding was 92.8 ± 4.0%. The 6-week, 1-year, and 3-year actuarial probabilities of survival were 79.8 ± 6.0%, 48.8 ± 7.7%, and 46.1 ± 7.9%, respectively. MELD score (hazard ratio (HR), 1.09 (95% confidence interval (CI), 1.01-1.17); p = .013) and ascites (HR, 2.84 (95% CI, 1.24-6.55); p = .014) were identified as significant predictors of survival. The 1-year actuarial probabilities of remaining free of new or worsening ascites and esophageal varices were 81.2 ± 8.7% and 89.2 ± 6.0%, respectively. No patients had overt hepatic encephalopathy during follow-up. MELD score significantly increased by a mean of 3.8 (95% CI, 1.7-6.0) at 3 months (p = .001). PVT had improved in 32.0%, worsened in 12.0%, and remained unchanged in 56.0% of patients at 3 months.

Conclusion: RTO may be effective for the prevention of variceal rebleeding in cirrhotic patients with PVT.

Key points: • Retrograde transvenous obliteration may prevent variceal rebleeding in cirrhotic patients with portal vein thrombosis. • The risks of other complications of portal hypertension may not be high after retrograde transvenous obliteration in cirrhotic patients with portal vein thrombosis. • Portal vein thrombosis may improve in approximately one-third of cirrhotic patients within 3 months after retrograde transvenous obliteration.
Full Text
https://link.springer.com/article/10.1007%2Fs00330-020-07109-9
DOI
10.1007/s00330-020-07109-9
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
Yonsei Authors
Han, Ki Chang(한기창) ORCID logo https://orcid.org/0000-0002-9701-9757
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/186987
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links